Free shipping on all orders over $ 500

PARP Poly-ADP-ribose polymerase

Cat.No.  Name Information
M13713 RK-287107 RK-287107 is a potent and specific tankyrase inhibitor with IC50s of 14.3 and 10.6 nM for tankyrase-1 and tankyrase-2, respectively. RK-287107 blocks colorectal cancer cell growth.
M4931 Rucaparib Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with Ki of 1.4 nM for PARP1, also showing binding affinity to eight other PARP domains.
M3932 NVP-TNKS656 NVP-TNKS656 is a highly potent, selective, and orally active TNKS2 inhibitor with IC50 of 6 nM; > 300 fold selectivity against PARP1 and PARP2.
M2215 Niraparib (MK-4827) MK-4827 (Niraparib) is a selective PARP1/2 inhibitor with an IC50 value of 3.8 nM/2.1 nM that increases the formation of PARP-DNA complexes through inhibition of PARPase activity, leading to DNA damage, apoptosis, PARP-1-dependent cell death (parthanatos) and cell death. Strong effector activity when acting on cancer cells harboring mutant BRCA-1 and BRCA-2. It is more than 330-fold more selective than PARP3, V-PARP and Tank1.
M1785 INO-1001 INO-1001 is a novel poly(ADP-ribose) polymerase (PARP) inhibitor with an IC50 of 3 nM.
M1732 Talazoparib (BMN-673) Talazoparib (BMN-673) is a highly potent, orally active PARP1/2 inhibitor.Talazoparib inhibits PARP1 and PARP2 enzyme activity with Kis of 1.2 nM and 0.87 nM, respectively. Talazoparib has antitumor activity.
M1664 AZD2281 (Olaparib) AZD 2281 (Olaparib, KU-0059436) is a potent PARP (poly ADP-ribose polymerase) inhibitorwith IC50 of 5 and 1 nM for PARP-1and PARP-2 respectively. Olaparib is an autophagy and mitophagy activator.
M45234 Basroparib Basroparib is an orally active selective inhibitor of end-anchor polymerase (TNKS) and an inhibitor of ribose polymerase (PARP) with antitumor activity.
M28680 Niraparib tosylate hydrate Niraparib (MK-4827) tosylate hydrate is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with IC50s of 3.8 and 2.1 nM, respectively. Niraparib tosylate hydrate leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity.
M25444 Senaparib Senaparib (IMP4297) is a highly potent, selective and orally active PARP1/2 inhibitor. Senaparib (IMP4297) exhibits strong antitumor activity.
M25398 Nudifloramide Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits poly(ADP-ribose) polymerase (PARP-1) activity in vitro.
M13714 Talazoparib tosylate Talazoparib tosylate (BMN 673ts) is a novel, potent and orally available PARP1/2 inhibitor with an IC50 of 0.57 nM for PARP1.
M13711 Niraparib hydrochloride Niraparib hydrochloride (MK-4827 hydrochloride) is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with IC50s of 3.8 and 2.1 nM, respectively.
M13392 GeA-69 GeA-69 is a cell-penetrating selective allosteric inhibitor targeting Macrodomain 2 (MD2) with a Kd of 2.1 µM.
M13391 RBN012759 RBN012759 is a potent, selective and orally active PARP14 inhibitor with IC50 values of <3 nM and 5 nM against the human and mouse catalytic domains, respectively. AIDS in the anti-tumor immune response.
M11443 KSQ-4279 USP1-IN-1 (USP1-IN-1, Formula I) is a first-in-class, selective allosteric USP1 small molecule inhibitor used in oncology research alone or in combination with PARP inhibition.
M10445 Fluzoparib (SHR3162) Fluzoparib (SHR3162) is an effective oral active PARP1 inhibitor (IC50=1.46±0.72 nM) with superior antitumor activity. Fluzoparib selectively inhibited the proliferation of homologous recombination repair (HR) deficient cells and sensitized HR deficient cells to cytotoxic drugs. Fluzoparib has good pharmacokinetic properties in vivo and can be used in cancer research.
M10298 AZD5305 AZD5305 is a potent and oral active, second-generation PARP (highly selective PARP1) inhibitor.
M9864 BRCA1-IN-2 BRCA1-IN-2 is a cell-permeable protein-protein interaction (PPI) inhibitor for BRCA1, with IC50 of 0.31 μM and Kd of 0.3 μM.
M9602 Atamparib (RBN-2397) Atamparib (RBN-2397) is a potent, orally active NAD+ competitive PARP7 inhibitor with an IC50 value of less than 3 nM. Atamparib (RBN-2397) can directly inhibit cell proliferation and restore type I interferon signaling by inhibiting PARP7 in tumor cells to stimulate innate or adaptive antitumor immune responses.

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.